The earnings call highlighted strong revenue growth, improved profitability, and successful product launches, indicating a strong start to 2025. However, challenges with commercial payer coverage for new products and the impact of a severe flu season were noted.

Company Guidance -

Q2 2025

During the recent earnings call, Exact Sciences provided guidance for 2025, highlighting several key metrics and growth drivers. The company expects total revenue for the year to be between $3.07 billion and $3.12 billion, an increase of $40 million at the midpoint, with second-quarter revenue projected to range from $765 million to $780 million. Screening revenue is anticipated to be between $2.39 billion and $2.425 billion for the year, while precision oncology revenue is forecasted to be between $680 million and $695 million. Additionally, Exact Sciences raised its adjusted EBITDA guidance to between $425 million and $455 million, reflecting an adjusted EBITDA margin of 14.2% at the midpoint. The company reported strong first-quarter results, with core revenue growth of 11%, adjusted EBITDA growth of 61%, and a 280 basis point expansion in adjusted EBITDA margin. Key growth drivers include the successful launch of Cologuard Plus, the expansion of the Rescreen program, and improvements in commercial execution, evidenced by a 30% increase in customer engagement and the addition of 190,000 new ordering providers.

Strong Revenue Growth

Core revenue grew by 11%, with first-quarter revenue $19 million above the midpoint of guidance. Screening revenue increased by 14% to $540 million.

Improved Profitability

Adjusted EBITDA increased by 61% to $63 million, with an adjusted EBITDA margin expansion of 280 basis points.

Successful Product Launches

Launched Cologuard Plus with Medicare coverage and Oncodetect, a molecular residual disease test, positioned for growth in precision oncology.

Customer Satisfaction and Engagement

Customer satisfaction reached an all-time high in Q1, and customer engagement by the field force increased by more than 30% year-over-year.

Cash Flow Improvements

Free cash flow reached break-even, a year-over-year improvement of $120 million.

Exact Sciences (EXAS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

EXAS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 06, 2025	2025 (Q2)	-0.13 / -	-0.09	―	―	―
May 01, 2025	2025 (Q1)	-0.38 / -0.54	-0.6	10.00% (+0.06)
Feb 19, 2025	2024 (Q4)	-0.31 / -4.67	-0.27	-1629.63% (-4.40)
Nov 05, 2024	2024 (Q3)	-0.20 / -0.21	0	―
Jul 31, 2024	2024 (Q2)	-0.34 / -0.09	-0.45	80.00% (+0.36)
May 08, 2024	2024 (Q1)	-0.48 / -0.60	-0.42	-42.86% (-0.18)
Feb 21, 2024	2023 (Q4)	-0.44 / -0.27	-0.72	62.50% (+0.45)
Nov 01, 2023	2023 (Q3)	-0.47 / 0.00	-0.84	―
Aug 01, 2023	2023 (Q2)	-0.49 / -0.45	-0.94	52.13% (+0.49)
May 09, 2023	2023 (Q1)	-0.74 / -0.42	-1.04	59.62% (+0.62)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

EXAS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 01, 2025	$47.16	$51.55	+9.31%
Feb 19, 2025	$50.48	$49.51	-1.92%
Nov 05, 2024	$71.51	$54.72	-23.48%
Jul 31, 2024	$45.68	$57.91	+26.77%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Exact Sciences Corp. (EXAS) report earnings?

Exact Sciences Corp. (EXAS) is schdueled to report earning on Aug 06, 2025, After Close (Confirmed).

What is Exact Sciences Corp. (EXAS) earnings time?

Exact Sciences Corp. (EXAS) earnings time is at Aug 06, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is EXAS EPS forecast?

EXAS EPS forecast for the fiscal quarter 2025 (Q2) is -0.13.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing